Grantham, Mayo, Van Otterloo & Co (GMO)
CVS icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s CVS Health CVS Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.6M Sell
634,846
-86,272
-12% -$6.65M 0.12% 75
2025
Q4 		$57.2M Sell
721,118
-39,834
-5% -$3.14M 0.15% 61
2025
Q3 		$57.4M Sell
760,952
-91,273
-11% -$6.26M 0.16% 63
2025
Q2 		$58.8M Sell
852,225
-89,142
-9% -$5.85M 0.18% 54
2025
Q1 		$63.8M Buy
941,367
+165,572
+21% +$9.91M 0.2% 49
2024
Q4 		$34.8M Sell
775,795
-118,525
-13% -$6.65M 0.11% 118
2024
Q3 		$56.2M Buy
894,320
+4,547
+0.5% +$265K 0.18% 66
2024
Q2 		$52.5M Buy
889,773
+173,083
+24% +$10.8M 0.18% 70
2024
Q1 		$57.2M Sell
716,690
-65,702
-8% -$5.02M 0.21% 66
2023
Q4 		$61.8M Sell
782,392
-55,527
-7% -$3.95M 0.27% 61
2023
Q3 		$58.5M Buy
837,919
+36,827
+5% +$2.61M 0.28% 67
2023
Q2 		$55.4M Buy
801,092
+71,404
+10% +$5.08M 0.26% 68
2023
Q1 		$54.2M Buy
729,688
+199,400
+38% +$16.7M 0.28% 67
2022
Q4 		$49.4M Buy
530,288
+158,588
+43% +$15.3M 0.26% 71
2022
Q3 		$35.4M Buy
371,700
+47,000
+14% +$4.65M 0.2% 93
2022
Q2 		$30.1M Buy
324,700
+83,900
+35% +$8.19M 0.16% 123
2022
Q1 		$24.4M Sell
240,800
-61,800
-20% -$6.49M 0.12% 167
2021
Q4 		$31.2M Sell
302,600
-81,200
-21% -$7.5M 0.15% 113
2021
Q3 		$32.6M Buy
383,800
+17,900
+5% +$1.5M 0.16% 104
2021
Q2 		$30.5M Buy
365,900
+50,768
+16% +$4.16M 0.15% 111
2021
Q1 		$23.7M Buy
315,132
+75,632
+32% +$5.51M 0.13% 125
2020
Q4 		$16.4M Buy
+239,500
New +$15.6M 0.1% 142
2018
Q1 		– Sell
-1,058,311
Closed -$75.9M – 581
2017
Q4 		$76.7M Sell
1,058,311
-6,700
-0.6% -$487K 0.45% 53
2017
Q3 		$86.6M Sell
1,065,011
-67,589
-6% -$5.35M 0.51% 49
2017
Q2 		$91.1M Buy
1,132,600
+29,310
+3% +$2.31M 0.5% 49
2017
Q1 		$86.6M Sell
1,103,290
-37,428
-3% -$2.99M 0.49% 53
2016
Q4 		$90M Sell
1,140,718
-3,764
-0.3% -$305K 0.49% 51
2016
Q3 		$102M Sell
1,144,482
-681,481
-37% -$64.3M 0.48% 46
2016
Q2 		$175M Sell
1,825,963
-493,133
-21% -$49.1M 0.72% 34
2016
Q1 		$241M Buy
2,319,096
+18,099
+0.8% +$1.76M 0.9% 29
2015
Q4 		$225M Sell
2,300,997
-96,900
-4% -$9.49M 0.81% 32
2015
Q3 		$231M Buy
2,397,897
+339,172
+16% +$35.7M 0.8% 27
2015
Q2 		$216M Buy
2,058,725
+1,009,700
+96% +$103M 0.7% 30
2015
Q1 		$108M Buy
1,049,025
+822,725
+364% +$83.2M 0.32% 61
2014
Q4 		$21.8M Sell
226,300
-121,500
-35% -$10.7M 0.06% 129
2014
Q3 		$27.7M Buy
347,800
+238,700
+219% +$18.8M 0.07% 124
2014
Q2 		$8.22M Sell
109,100
-1,539,981
-93% -$116M 0.02% 217
2014
Q1 		$123M Sell
1,649,081
-1,696,273
-51% -$120M 0.32% 61
2013
Q4 		$239M Buy
3,345,354
+442,526
+15% +$28.4M 0.58% 34
2013
Q3 		$165M Buy
2,902,828
+595,854
+26% +$35.5M 0.43% 47
2013
Q2 		$132M Buy
+2,306,974
New +$134M 0.34% 48

Other funds holding CVS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s CVS Position: Q1 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) reduced its CVS Health (CVS) stake by 12% in Q1 2026, selling an estimated $6.65M and leaving 634,846 shares worth $45.6M. The position accounts for 0.12% of the portfolio, ranked #75.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in CVS in Q2 2013 and has held it in 41 quarters since. The position peaked at $241M in Q1 2016. 1,865 funds tracked by Wall St. Rank hold CVS as of Q1 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) held 634,846 shares of CVS Health worth $45.6M as of Q1 2026.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 86,272 CVS Health shares in Q1 2026, an estimated $6.65M.
  • CVS Health made up 0.12% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q1 2026, its #75 holding.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in CVS Health in Q2 2013 and has held it in 41 quarters since.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s CVS Health position peaked at $241M in Q1 2016.
  • 1,865 funds tracked by Wall St. Rank held CVS Health as of Q1 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2026, filed 14 May 2026.